Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD34+ Enriched Transplants for Hematologic Malignancies
NCT04282174Phase 2Withdrawn
- Sponsor
- Baptist Health South Florida
- Start
- Sep 2022
- Primary completion
- Mar 2030
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of CD34+ enriched hematopoietic stem cells in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), sponsored by Baptist Health South Florida. Planned start Sep 2022; status: withdrawn.
02
Drugs
CD34+ enriched hematopoietic stem cells
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)chronic myelogenous leukemia (CML)chronic lymphocytic leukemia (CLL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT04282174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04282174.